Freenome, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FRNM | NEO | PSNL | BLLN | ADPT | BDSX | |
|---|---|---|---|---|---|---|
| Market cap | 1.21B | 2.22B | 1.69B | 5.37B | 4.26B | 226.74M |
| P/E (TTM) | — | — | — | 180.8 | — | — |
| Forward P/E | -4.7 | 54.5 | -16.3 | 76.7 | -148.2 | -97.7 |
| Price/book | -0.2 | 2.8 | 6.2 | 9.9 | 18.8 | 24.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +5.31% | +64.90% | +119.76% | +4.54% | +71.66% | +175.87% |
| Today | −1.48% | +1.90% | +0.25% | +3.11% | +3.53% | +2.09% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All FRNM news ›Freenome, Roche Protein Tests Don't Boost Lung Cancer Screening
Freenome, Roche Blood Protein Tests Fail to Improve Lung Cancer CT Screening Accuracy GenomeWeb Freenome, Roche Blood Protein Tests Fail to Improve Lung Cancer CT Screening Accuracy
Freenome SimpleScreen Lung
GenomeWeb Freenome has launched its SimpleScreen Lung laboratory-developed test for lung cancer screening The test is intended for adults ages 50 to 80 with a âÂÂ¥20 pack-year smoking history who are not currently participating in…
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
Eligible patients can order the lung test alone or add FDA-approved colorectal cancer screening through the same blood draw. FDA granted Breakthrough Device Designation to SimpleScreen Lung for eligible high-risk adults. FDA approved…
Cathie Wood’s ARK Sells Personalised, Buys Freenome and Rocket Lab Shares
Cathie Wood’s ARK Invest made several trades this week, selling some healthcare stocks and buying others. It also added to its Rocket Lab position after the share price dropped. ARK published its daily trades for Friday, October 16, 2026.…
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
The Manila Times Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026 BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test. For clinicians, the central question is whether improved precancerous lesion detection will…
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade…
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Detailed results will be presented at ACG on October 14, 2026. The first-generation test received FDA approval in July 2026 and launched commercially in the United States through Abbott Cancer Diagnostics in late September. FDA approved…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- coincentral.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.